Symbols / ADAG Stock $3.53 -0.84% Adagene Inc.

Healthcare • Biotechnology • China • NGM
ADAG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Peter P. Luo Ph.D.
Exch · Country NGM · China
Market Cap 233.24M
Enterprise Value 156.15M
Income -17.61M
Sales 7.67M
FCF (ttm) -10.25M
Book/sh 0.75
Cash/sh 1.28
Employees 128
Insider 10d —
IPO Feb 09, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.79
PEG —
P/S 30.41
P/B 4.73
P/C —
EV/EBITDA -7.44
EV/Sales 20.36
Quick Ratio 3.01
Current Ratio 3.07
Debt/Eq 12.07
LT Debt/Eq —
EPS (ttm) -0.37
EPS next Y -0.52
EPS Growth —
Revenue Growth 73.33%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-04-28
Earnings (prior) 2023-04-28
ROA -16.00%
ROE -34.39%
ROIC —
Gross Margin 100.00%
Oper. Margin -74.96%
Profit Margin -229.56%
Shs Outstand 66.07M
Shs Float 41.42M
Insider Own 11.07%
Instit Own 20.66%
Short Float 0.73%
Short Ratio 1.29
Short Interest 411.32K
52W High 4.75
vs 52W High -25.68%
52W Low 1.30
vs 52W Low 171.54%
Beta 0.59
Impl. Vol. —
Rel Volume 0.58
Avg Volume 240.98K
Volume 140.09K
Target (mean) $9.40
Tgt Median $8.00
Tgt Low $7.00
Tgt High $14.00
# Analysts 5
Recom Strong_buy
Prev Close $3.56
Price $3.53
Change -0.84%
About

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.40
Mean price target
2. Current target
$3.53
Latest analyst target
3. DCF / Fair value
$-2.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.53
Low
$7.00
High
$14.00
Mean
$9.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-06 main Guggenheim Buy → Buy $10
2025-11-24 init Guggenheim — → Buy $9
2025-09-18 init LUCID CAPITAL MARKETS — → Buy $9
2025-08-15 main HC Wainwright & Co. Buy → Buy $7
2025-08-06 init Leerink Partners — → Outperform $7
2025-04-03 reit HC Wainwright & Co. Buy → Buy $8
2025-01-27 main HC Wainwright & Co. Buy → Buy $8
2024-09-18 reit HC Wainwright & Co. Buy → Buy $5
2024-07-22 reit HC Wainwright & Co. Buy → Buy $5
2024-06-28 reit HC Wainwright & Co. Buy → Buy $5
2023-10-04 reit HC Wainwright & Co. Buy → Buy $5
2023-09-01 reit HC Wainwright & Co. Buy → Buy $5
2023-04-21 reit HC Wainwright & Co. — → Buy $5
2023-03-29 reit HC Wainwright & Co. — → Buy $5
2023-03-21 reit HC Wainwright & Co. — → Buy $5
2023-01-24 main Morgan Stanley — → Overweight $5
2022-12-07 init HC Wainwright & Co. — → Buy $5
2022-09-09 main Morgan Stanley — → Overweight $7
2022-02-01 main Morgan Stanley — → Overweight $15
2022-01-06 main Morgan Stanley — → Overweight $27
News
RSS: Latest ADAG news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
7.67
+7332.76%
0.10
-99.43%
18.11
+94.90%
9.29
Operating Revenue
7.67
+7332.76%
0.10
-99.43%
18.11
+94.90%
9.29
Operating Expense
29.11
-19.26%
36.05
-13.81%
41.83
-55.12%
93.21
Research And Development
22.03
-23.45%
28.78
-21.45%
36.64
-54.96%
81.34
Selling General And Administration
7.08
-2.72%
7.27
-16.14%
8.67
-26.96%
11.87
General And Administrative Expense
7.08
-2.72%
7.27
-16.14%
8.67
-26.96%
11.87
Other Gand A
7.08
-2.72%
7.27
-16.14%
8.67
-26.96%
11.87
Other Operating Expenses
—
—
-3.48
—
Total Expenses
29.11
-19.26%
36.05
-13.81%
41.83
-55.12%
93.21
Operating Income
-21.44
+40.37%
-35.95
-51.57%
-23.72
+71.74%
-83.92
Total Operating Income As Reported
-21.44
+40.37%
-35.95
-51.57%
-23.72
+71.74%
-83.92
EBITDA
-16.85
+46.75%
-31.65
-111.87%
-14.94
+80.69%
-77.37
Normalized EBITDA
-18.22
+40.74%
-30.74
-87.64%
-16.38
+79.50%
-79.93
Reconciled Depreciation
0.59
-37.18%
0.94
-22.31%
1.21
-16.63%
1.45
EBIT
-17.44
+46.47%
-32.59
-101.83%
-16.15
+79.51%
-78.82
Total Unusual Items
1.37
+250.76%
-0.91
-162.66%
1.45
-43.40%
2.56
Total Unusual Items Excluding Goodwill
1.37
+250.76%
-0.91
-162.66%
1.45
-43.40%
2.56
Net Income
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Pretax Income
-17.91
+46.45%
-33.44
-93.81%
-17.25
+78.30%
-79.51
Net Non Operating Interest Income Expense
1.84
-37.59%
2.95
-7.11%
3.18
+1105.40%
-0.32
Interest Expense Non Operating
0.46
-45.63%
0.85
-23.10%
1.11
+59.78%
0.69
Net Interest Income
1.84
-37.59%
2.95
-7.11%
3.18
+1105.40%
-0.32
Interest Expense
0.46
-45.63%
0.85
-23.10%
1.11
+59.78%
0.69
Interest Income Non Operating
2.30
-39.39%
3.80
-11.25%
4.28
+1034.59%
0.38
Interest Income
2.30
-39.39%
3.80
-11.25%
4.28
+1034.59%
0.38
Other Income Expense
1.69
+484.48%
-0.44
-113.36%
3.29
-30.36%
4.72
Other Non Operating Income Expenses
0.32
-30.57%
0.47
-74.69%
1.84
-14.99%
2.17
Gain On Sale Of Security
1.37
+250.76%
-0.91
-162.66%
1.45
-43.40%
2.56
Tax Provision
-0.30
-1596.92%
-0.02
-101.04%
1.69
+268.45%
0.46
Tax Rate For Calcs
0.00
+3068.19%
0.00
-99.79%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.02
+4877.45%
-0.00
-100.13%
0.36
-43.40%
0.64
Net Income Including Noncontrolling Interests
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Net Income From Continuing Operation Net Minority Interest
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Net Income From Continuing And Discontinued Operation
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Net Income Continuous Operations
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Normalized Income
-18.95
+41.72%
-32.52
-62.34%
-20.03
+75.54%
-81.89
Net Income Common Stockholders
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Otherunder Preferred Stock Dividend
—
—
0.00
0.00
Diluted EPS
—
-0.74
-68.57%
-0.44
+76.35%
-1.85
Basic EPS
—
-0.74
-68.57%
-0.44
+76.35%
-1.85
Basic Average Shares
—
45.03
+2.83%
43.79
+1.11%
43.31
Diluted Average Shares
—
45.03
+2.83%
43.79
+1.11%
43.31
Diluted NI Availto Com Stockholders
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
89.27
-22.86%
115.73
-24.06%
152.40
—
Current Assets
87.78
-22.62%
113.44
-24.02%
149.32
—
Cash Cash Equivalents And Short Term Investments
85.19
-22.50%
109.93
-23.53%
143.76
—
Cash And Cash Equivalents
85.19
-22.50%
109.93
-23.53%
143.76
—
Receivables
0.01
-96.26%
0.22
-64.16%
0.62
—
Accounts Receivable
—
—
0.00
-100.00%
3.00
Gross Accounts Receivable
—
—
0.00
-100.00%
3.00
Allowance For Doubtful Accounts Receivable
—
—
0.00
0.00
Prepaid Assets
2.05
-14.04%
2.38
-42.36%
4.13
—
Other Current Assets
0.53
-41.72%
0.91
+12.48%
0.80
—
Total Non Current Assets
1.49
-34.78%
2.29
-25.91%
3.08
—
Net PPE
1.41
-35.96%
2.20
-26.04%
2.97
—
Gross PPE
8.71
-2.23%
8.91
+0.27%
8.88
—
Accumulated Depreciation
-7.30
-8.84%
-6.71
-13.52%
-5.91
—
Properties
0.00
0.00
0.00
—
Buildings And Improvements
0.28
-22.31%
0.37
+90.28%
0.19
—
Machinery Furniture Equipment
5.60
-1.49%
5.69
-1.49%
5.77
—
Other Properties
1.79
-1.39%
1.82
-2.45%
1.86
—
Leases
1.03
-0.66%
1.04
-1.67%
1.06
—
Other Non Current Assets
0.08
-4.12%
0.08
-22.53%
0.11
—
Total Liabilities Net Minority Interest
38.74
-14.22%
45.17
-34.83%
69.31
—
Current Liabilities
38.18
+21.39%
31.46
-42.89%
55.08
—
Payables And Accrued Expenses
20.19
-11.20%
22.74
-12.83%
26.09
—
Payables
17.92
-12.05%
20.37
-12.71%
23.34
—
Accounts Payable
4.24
+37.11%
3.09
-15.61%
3.67
—
Current Accrued Expenses
2.28
-3.90%
2.37
-13.82%
2.75
—
Total Tax Payable
0.49
-13.70%
0.56
+61.34%
0.35
—
Income Tax Payable
0.01
-90.04%
0.05
0.00
—
Current Debt And Capital Lease Obligation
17.93
+108.70%
8.59
-37.60%
13.77
—
Current Debt
17.79
+111.89%
8.40
-38.34%
13.62
—
Other Current Borrowings
12.92
+210.55%
4.16
+46.01%
2.85
—
Current Capital Lease Obligation
0.14
-27.87%
0.20
+28.93%
0.15
—
Current Deferred Liabilities
0.00
0.00
-100.00%
15.11
—
Current Deferred Revenue
0.00
0.00
-100.00%
15.11
—
Other Current Liabilities
0.06
-53.01%
0.12
+7.00%
0.11
—
Total Non Current Liabilities Net Minority Interest
0.56
-95.92%
13.71
-3.62%
14.23
—
Long Term Debt And Capital Lease Obligation
0.56
-95.92%
13.71
-3.43%
14.20
—
Long Term Debt
0.42
-96.92%
13.54
-4.29%
14.15
—
Long Term Capital Lease Obligation
0.14
-18.06%
0.17
+222.58%
0.05
—
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.04
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.04
Other Non Current Liabilities
—
—
0.03
-69.48%
0.09
Preferred Securities Outside Stock Equity
0.00
—
—
0.00
Stockholders Equity
50.52
-28.40%
70.56
-15.08%
83.09
—
Common Stock Equity
50.52
-28.40%
70.56
-15.08%
83.09
—
Capital Stock
0.01
+6.17%
0.01
+0.91%
0.01
—
Common Stock
0.01
+6.17%
0.01
+0.91%
0.01
—
Share Issued
58.89
+6.78%
55.15
+2.00%
54.07
—
Ordinary Shares Number
58.89
+6.78%
55.15
+2.00%
54.07
—
Treasury Shares Number
0.00
-100.00%
0.00
+0.00%
0.00
-100.00%
0.09
Additional Paid In Capital
362.22
+3.46%
350.11
+2.15%
342.74
—
Retained Earnings
-311.18
-12.03%
-277.75
-7.32%
-258.81
—
Gains Losses Not Affecting Retained Earnings
-0.53
+70.73%
-1.80
-111.95%
-0.85
—
Treasury Stock
0.00
-100.00%
0.00
+0.00%
0.00
-100.00%
0.62
Other Equity Adjustments
-0.53
+70.73%
-1.80
-111.95%
-0.85
—
Total Equity Gross Minority Interest
50.52
-28.40%
70.56
-15.08%
83.09
—
Total Capitalization
50.94
-39.43%
84.10
-13.51%
97.24
—
Working Capital
49.59
-39.51%
81.99
-13.00%
94.24
—
Invested Capital
68.73
-25.69%
92.50
-16.56%
110.86
—
Total Debt
18.49
-17.09%
22.31
-20.25%
27.97
—
Capital Lease Obligations
0.28
-23.26%
0.37
+79.58%
0.21
—
Net Tangible Assets
50.52
-28.40%
70.56
-15.08%
83.09
—
Tangible Book Value
50.52
-28.40%
70.56
-15.08%
83.09
—
Duefrom Related Parties Current
0.01
-96.26%
0.22
-64.16%
0.62
—
Dueto Related Parties Current
13.19
-21.10%
16.71
-13.50%
19.32
—
Line Of Credit
4.87
+14.95%
4.24
-60.67%
10.77
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.66
+47.28%
-29.70
-4.38%
-28.45
+41.47%
-48.61
Cash Flow From Continuing Operating Activities
-15.66
+47.28%
-29.70
-4.38%
-28.45
+41.47%
-48.61
Net Income From Continuing Operations
-17.61
+47.32%
-33.42
-76.41%
-18.95
+76.31%
-79.97
Depreciation Amortization Depletion
0.59
-37.18%
0.94
-22.31%
1.21
-16.63%
1.45
Depreciation
0.59
-37.18%
0.94
-22.31%
1.21
-16.63%
1.45
Depreciation And Amortization
0.59
-37.18%
0.94
-22.31%
1.21
-16.63%
1.45
Other Non Cash Items
-0.24
+79.07%
-1.14
—
—
Stock Based Compensation
3.74
-23.79%
4.91
-32.48%
7.27
-30.88%
10.52
Operating Gains Losses
-1.36
-250.18%
0.91
+163.24%
-1.44
+43.62%
-2.55
Gain Loss On Investment Securities
-0.05
—
—
—
Net Foreign Currency Exchange Gain Loss
-1.32
-245.47%
0.91
+162.66%
-1.45
+43.40%
-2.56
Gain Loss On Sale Of PPE
0.00
-40.60%
0.00
-73.59%
0.01
+37.50%
0.01
Change In Working Capital
-0.78
+58.99%
-1.89
+88.58%
-16.55
-175.45%
21.94
Change In Receivables
-0.01
-104.23%
0.21
-46.22%
0.40
-94.23%
6.89
Changes In Account Receivables
—
0.00
0.00
-100.00%
3.00
Change In Prepaid Assets
-0.27
-137.39%
0.72
-56.10%
1.65
+287.19%
-0.88
Change In Payables And Accrued Expense
-3.86
-47.94%
-2.61
+19.67%
-3.25
-148.37%
6.72
Change In Accrued Expense
-0.07
+62.14%
-0.19
-51.79%
-0.12
+85.17%
-0.82
Change In Payable
-3.79
-56.35%
-2.43
+22.46%
-3.13
-141.47%
7.54
Change In Account Payable
-1.36
-218.23%
1.15
+300.57%
-0.57
-266.14%
0.34
Change In Other Working Capital
3.46
—
-15.11
-257.97%
9.56
Change In Other Current Assets
0.06
+1505.12%
0.00
-85.83%
0.02
+161.26%
-0.04
Change In Other Current Liabilities
-0.15
+31.53%
-0.22
+17.05%
-0.27
+14.32%
-0.31
Investing Cash Flow
0.48
-57.05%
1.11
+1535.09%
-0.08
+88.72%
-0.69
Cash Flow From Continuing Investing Activities
0.48
-57.05%
1.11
+1535.09%
-0.08
+88.72%
-0.69
Net PPE Purchase And Sale
-0.02
+53.15%
-0.03
+56.81%
-0.08
+88.72%
-0.69
Purchase Of PPE
-0.02
+49.22%
-0.03
+60.50%
-0.09
+87.70%
-0.69
Sale Of PPE
0.00
+728.40%
0.00
-97.79%
0.01
+56.50%
0.00
Capital Expenditure
-0.02
+49.22%
-0.03
+60.50%
-0.09
+87.70%
-0.69
Net Investment Purchase And Sale
0.49
-56.94%
1.14
0.00
0.00
Purchase Of Investment
-80.00
+37.74%
-128.50
-173.40%
-47.00
0.00
Sale Of Investment
80.49
-37.91%
129.64
+175.84%
47.00
0.00
Financing Cash Flow
4.45
+17.94%
3.77
+170.23%
-5.37
-130.11%
17.82
Cash Flow From Continuing Financing Activities
4.45
+17.94%
3.77
+170.23%
-5.37
-130.11%
17.82
Net Issuance Payments Of Debt
-12.24
-257.51%
-3.42
+36.26%
-5.37
-125.02%
21.48
Issuance Of Debt
5.64
+14.59%
4.92
-39.54%
8.13
-68.51%
25.83
Repayment Of Debt
-17.88
-114.30%
-8.34
+38.23%
-13.51
-210.23%
-4.35
Long Term Debt Issuance
5.64
+14.59%
4.92
-39.54%
8.13
-68.51%
25.83
Long Term Debt Payments
-17.88
-114.30%
-8.34
+38.23%
-13.51
-210.23%
-4.35
Net Long Term Debt Issuance
-12.24
-257.51%
-3.42
+36.26%
-5.37
-125.02%
21.48
Net Common Stock Issuance
0.00
-100.00%
7.33
0.00
+100.00%
-3.98
Common Stock Payments
—
0.00
0.00
+100.00%
-3.98
Repurchase Of Capital Stock
—
0.00
0.00
+100.00%
-3.98
Proceeds From Stock Option Exercised
0.14
-22.43%
0.18
+3140.98%
0.01
-98.30%
0.32
Net Other Financing Charges
—
-0.32
—
—
Changes In Cash
-10.74
+56.75%
-24.82
+26.78%
-33.90
-7.70%
-31.47
Effect Of Exchange Rate Changes
0.06
-21.16%
0.08
+9.59%
0.07
-91.13%
0.84
Beginning Cash Position
85.19
-22.50%
109.93
-23.53%
143.76
-17.57%
174.39
End Cash Position
74.52
-12.53%
85.19
-22.50%
109.93
-23.53%
143.76
Free Cash Flow
-15.67
+47.29%
-29.73
-4.19%
-28.54
+42.11%
-49.30
Interest Paid Supplemental Data
0.40
-48.24%
0.78
-25.69%
1.05
+73.56%
0.60
Income Tax Paid Supplemental Data
0.00
-95.28%
0.03
-97.53%
1.38
-43.41%
2.43
Change In Income Tax Payable
0.40
+950.36%
-0.05
-190.04%
0.05
+103.19%
-1.66
Change In Tax Payable
0.40
+950.36%
-0.05
-190.04%
0.05
+103.19%
-1.66
Common Stock Issuance
0.00
-100.00%
7.33
0.00
0.00
Issuance Of Capital Stock
16.55
+125.75%
7.33
0.00
0.00
Net Preferred Stock Issuance
16.55
0.00
0.00
—
Preferred Stock Issuance
16.55
0.00
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category